Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2024 · 10-Q
Revenue—
Net Income-$6.90M-$6.90MN/M vs Q1 2023 EPS Diluted-$0.38-$0.38N/M vs Q1 2023 Operating Cash Flow$2,118,000N/M Free Cash Flowderived$2,086,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end